The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab
摘要
With great interest we have read the comment of Dr.Khakoo on the recently published CRAFITY score for the prediction of response to anti-programmed death(ligand)1[PD-(L)1]-based immunotherapy in patients with unresectable hepatocellular carcinoma(HCC)(1).
-
1方守諾,幸曉華,頼一凡.Bevacizumab眼科治療進展[J].镜湖医学,2009,9(1):77-79.
-
2Shinji Itoh,Masafumi Ikeda.Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma[J].Hepatobiliary Surgery and Nutrition,2022,11(6):876-878.
-
3Manal M. El-Mahdy,Riham A. Ibrahim,Radwa M. Hamed,Mohamaad S. Elkady,Walid A. Bayoumy,Zeinab M. Elsayed,Mai M. Ezz-El-Din.Prediction of Response to Neoadjuvant Chemotherapy in Egyptian Patients with Locally Advanced Breast Cancer: The Evolving Role of Tumour Infiltrating Lymphocytes (TILs)[J].Journal of Cancer Therapy,2020,11(4):206-219.
-
4Gurjot Singh,Eric M Yoshida,Sahaj Rathi,Vladimir Marquez,Peter Kim,Siegfried R Erb,Baljinder S Salh.Biomarkers for hepatocellular cancer[J].World Journal of Hepatology,2020,12(9):558-573. 被引量：2
-
5Pankaj Gupta,Gaurav Chayan Das,Akash Bansal,Jayanta Samanta,Harshal S Mandavdhare,Vishal Sharma,Shano Naseem,Vikas Gupta,Thakur Deen Yadav,Usha Dutta,Neelam Varma,Manavjit Singh Sandhu,Rakesh Kochhar.Value of neutrophil-lymphocyte ratio in evaluating response to percutaneous catheter drainage in patients with acute pancreatitis[J].World Journal of Clinical Cases,2022,10(1):91-103. 被引量：1
-
6Joao Miranda,Natally Horvat,Gilton Marques Fonseca,Jose de Arimateia Batista Araujo-Filho,Maria ClaraFernandes,Charlotte Charbel,Jayasree Chakraborty,Fabricio Ferreira Coelho,Cesar Higa Nomura,Paulo Herman.Current status and future perspectives of radiomics in hepatocellular carcinoma[J].World Journal of Gastroenterology,2023,29(1):43-60. 被引量：5
-
7Xin-Yu Liu,Hao Tang,Qing-Yang Zhou,Yan-Lin Zeng,Dan Chen,Hui Xu,Yue Li,Bei Tan,Jia-Ming Qian.Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology[J].World Journal of Gastroenterology,2023,29(2):272-285. 被引量：1
-
8Takeshi Hatanaka,Atsushi Naganuma,Yutaka Yata,Satoru Kakizaki.Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?[J].Hepatobiliary Surgery and Nutrition,2022,11(6):927-930. 被引量：1
-
9Wattana Leowattana,Tawithep Leowattana,PathompThep Leowattana.Systemic treatment for unresectable hepatocellular carcinoma[J].World Journal of Gastroenterology,2023,29(10):1551-1568. 被引量：3
-
10植保所揭示昆虫免疫系统对Bt毒素的重要解毒作用[J].山东农药信息,2022(6):24-24.
